Amgen, Immunex regulatory update

The Biological Response Modifier's Advisory Committee unanimously voted to recommend FDA approval of Amgen Inc.'s Neupogen G-CSF and Immunex Corp.'s Leukine GM-CSF white blood cell stimulants for use in peripheral blood progenitor cell (PBPC) transplantation.

Studies presented at the meeting indicated that PBPC transplantation in conjunction with Leukine and Neupogen results in shorter hospitalizations and greatly reduced costs compared to bone marrow transplantation. ...